In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
about
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' PerspectivesUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisHighlight on advances in nontuberculous mycobacterial disease in North America.Disseminated infection by Mycobacterium sherrisii and Histoplasma capsulatum in an African HIV-infected patientResponse to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung DiseaseClinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in RatsSafety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients.Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.Mycobacterium abscessus Complex - a Particular Challenge in the Setting of Lung Transplantation.Draft Genome Sequence of Mycobacterium cosmeticum DSM 44829.Antibiotic treatment for nontuberculous mycobacterial lung disease.Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment.Treatment of Non-Tuberculous Mycobacterial Lung Disease.Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China.[Nontuberculous mycobacterial pulmonary disease].Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives.Mycobacterium abscessus Complex Infections: A Retrospective Cohort Study.NTM drug discovery: status, gaps and the way forward.Emergence of Mycobacterium simiae: A retrospective study from a tertiary care center in Lebanon.Teicoplanin - Tigecycline Combination Shows Synergy Against Mycobacterium abscessus.Novel Mutations Associated with Clofazimine Resistance in Mycobacterium abscessusClofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche
P2860
Q26749480-38EE8A38-BC36-4C22-B9CC-9456249A169FQ26775974-C54BF181-6FE4-41E3-9405-B1DA568AAF3FQ27028191-4B14D82C-B347-4FD4-8778-30F1BA018513Q30590405-D7E446CC-74FF-452C-AF4E-27E15A0B4C93Q35859886-D575BDA4-3EB0-4CFC-8F6A-483D3571FF84Q36099490-9FD13CA6-0679-45B5-98DC-D64B8F0F8D53Q36567746-23086503-7C27-4337-A4BF-399002815999Q36571826-A7F76500-3497-4A05-8092-A6E939A5634BQ37358621-D9D1D163-E45C-46BE-8C24-F89FD432F35EQ38332104-117C9498-140B-46F9-909A-69E4F5F01B93Q38404398-995B03F8-E569-422F-B17D-9280B5624CE2Q38687467-5DB064B4-8B89-432F-80BD-C9642C1E9418Q38704873-018702A5-1D61-4244-9CB4-5BD1E36E2254Q38770072-B89F3142-3478-4FBD-88C2-213BE8634C8AQ38969052-4F912823-890D-4F02-9946-0B027224B4BFQ39321216-C1B5D51A-BCB5-4644-9235-11548353A7D0Q40560387-1FDEF847-8B21-499E-A177-FF4228C098E5Q40818353-44DBB1AF-8F89-4193-842A-915C4E9BB0DFQ47756838-EFC76058-4891-4C00-A548-849D20B62B3DQ49622474-1092CC14-333B-47C3-A394-A6B55872A0B3Q52596288-1F635A72-30D9-4EF4-BB7C-537E5D8FEC54Q53698475-FFB3E4B9-CDF9-4B47-B3DD-268262E29647Q55381713-0524A3B6-435F-44EF-B44A-358698D0F2C0Q57179151-485EB23E-4E6B-4524-BF69-72E8CC9EF814Q57945933-6AD483C4-4B16-4D98-A0F1-0670E57906A5
P2860
In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
In vitro synergy between clofa ...... rculous mycobacterial disease.
@ast
In vitro synergy between clofa ...... rculous mycobacterial disease.
@en
type
label
In vitro synergy between clofa ...... rculous mycobacterial disease.
@ast
In vitro synergy between clofa ...... rculous mycobacterial disease.
@en
prefLabel
In vitro synergy between clofa ...... rculous mycobacterial disease.
@ast
In vitro synergy between clofa ...... rculous mycobacterial disease.
@en
P2093
P2860
P356
P1476
In vitro synergy between clofa ...... rculous mycobacterial disease.
@en
P2093
Charles L Daley
Leonid B Heifets
Martin J Boeree
Niels K Helstrom
Sarah E Totten
P2860
P304
P356
10.1128/AAC.01505-12
P407
P577
2012-10-01T00:00:00Z